CHAPTER 1. INTRODUCTION
1.1. Market Definition
1.2. Executive Summary
1.3. The Scope of the Study
CHAPTER 2. RESEARCH METHODOLOGY
2.1. Secondary Research
2.2. Primary Research
2.3. Analytic Tools and Model
2.4. Economic Indicator
2.4.1 Base Year, Base Currency, Forecasting Period
2.5. Expert Validation
2.6. Study Timeline
CHAPTER 3. MARKET ANALYSIS
3.1. Industry Value Chain Analysis
3.2. Porter's Five Force Analysis
3.2.1. Bargaining Power of Buyers
3.2.2. Bargaining Power of Suppliers
3.2.3. Threats of Substitutes
3.2.4. Threats of New Entrants
3.2.5. Degree of Competition
3.3. PESTLE Analysis
3.3.1. Political
3.3.2. Economical
3.3.3. Social
3.3.4. Technological
3.3.5. Legal
3.3.6. Environmental
3.4. SWOT Analysis
3.4.1. Strengths
3.4.2. Weakness
3.4.3. Opportunities
3.4.4. Threats
3.5. Y-O-Y Analysis
CHAPTER 4. MARKET DYNAMICS
4.1. Market Drivers & Opportunities
4.1.1. Increase in the number of organ transplant procedures
4.1.2. Use of TDM in traditional anticancer therapies
4.1.3. Monitoring of biosimilar in autoimmune diseases
4.2. Market Restraints & Challenges
4.2.1. The reluctance of small hospitals to offer TDM services
4.2.2. Operational barriers faced in conducting TDM tests
CHAPTER 5. GLOBAL THERAPEUTIC DRUG MONITORING MARKET– BY
PRODUCT
5.1. Consumables
5.2. Equipment
5.2.1. Clinical Chemistry Analyzers
5.2.2. Chromatography and MS Detectors
5.2.3. Immunoassay Analyzers
CHAPTER 6. GLOBAL THERAPEUTIC DRUG MONITORING MARKET – BY
TECHNOLOGY
6.1. Immunoassays
6.1.1. Chemiluminescent Immunoassays
6.1.2. Fluorescence Immunoassays
6.2. Radioimmunoassay
6.3. Colourimetric Immunoassays
6.4. Other Immunoassays
6.5. Chromatography-MS
6.5.1. Liquid Chromatography/Mass Spectrometry (LC-MS)
6.5.2. Gas Chromatography-Mass Spectrometry
CHAPTER 7. GLOBAL THERAPEUTIC DRUG MONITORING MARKET – BY
CLASS OF DRUG
7.1. Antiepileptic Drugs
7.2. Immunosuppressant Drugs
7.3. Antiarrhythmic Drugs
7.4. Bronchodilator Drugs
7.5. Antibiotic Drugs
7.6. Psychoactive Drugs
7.7. Other Drug Classes
CHAPTER 8. GLOBAL THERAPEUTIC DRUG MONITORING MARKET - BY END
USER
8.1. Hospital Laboratories
8.2. Commercial/Private Laboratories
8.3. Other End Users
CHAPTER 9. GLOBAL THERAPEUTIC DRUG MONITORING MARKET - BY
GEOGRAPHY
9.1. Introduction
9.2. North America
9.2.1. U.S.
9.2.2. Canada
9.2.3. Mexico
9.2.4. Costa Rica
9.3. South America
9.3.1. Brazil
9.3.2. Argentina
9.3.3. Chile
9.3.4. Columbia
9.3.5. Others
9.4. Europe
9.4.1. U.K.
9.4.2. Germany
9.4.3. France
9.4.4. Italy
9.4.5. Spain
9.4.6. Russia
9.4.7. Netherlands
9.4.8. Switzerland
9.4.9. Poland
9.4.10. Others
9.5. APAC
9.5.1. China
9.5.2. Japan
9.5.3. India
9.5.4. South Korea
9.5.5. Australia & New Zealand
9.5.6. Malaysia
9.5.7. Singapore
9.5.8. Others
8.6. Middle East & Africa
9.6.1. UAE
9.6.2. Saudi Arabia
9.6.3. Iran
9.6.4. Iraq
9.6.5. Qatar
9.6.6. South Africa
9.6.7. Algeria
9.6.8. Morocco
9.6.9. Nigeria
9.6.10. Egypt
9.6.11. Others
CHAPTER 10. GLOBAL THERAPEUTIC DRUG MONITORING MARKET -
COMPANY PROFILES
10.1. Abbott Laboratories Pharmaceutical Company
10.2. F. Hoffmann-La Roche Ltd.
10.3. Siemens Healthineers Healthcare Company
10.4. Thermo Fisher Scientific Company
10.5. Danaher Corporation
10.6. Bio-Rad Laboratories Company
10.7. Biomérieux Biotechnology Company
10.8. Bühlmann Laboratories AG
10.9. Sekisui Medical Co., Ltd.
10.10. Randox Laboratories Company
CHAPTER 11. GLOBAL THERAPEUTIC DRUG MONITORING MARKET –
COMPETITIVE LANDSCAPE
11.1. Market Share Analysis
11.2. Strategies adopted by top companies
11.3. Mergers, Acquisitions, Collaborations & Agreements
CHAPTER 12. MARKET INSIGHTS
12.1. Industry Experts Insights
12.2. Analysts Opinions
12.3. Investment Opportunities
CHAPTER 13. APPENDIX
13.1. List of Tables
13.2. List of Figures
